Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06990477
Recruiting Not applicable

Effect of EIT-guided PEEP in ARDS Patients

NCT06990477 · tracked via the Priya Life Science South Korea tracker
Sponsor
Southeast University, China
Phase
Not applicable
Started
2026-03-13
Last updated
2026-07-10

Condition(s) studied

ARDS (Acute Respiratory Distress Syndrome)

Investigational drug(s) / intervention(s)

EIT-guided PEEP

EIT-guided PEEP: PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O or to 24cmH2O and then reduced in steps of 2cmH2O from 20 to 4 every 30s.

Study summary

Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury. Positive end-expiratory pressure (PEEP), as one of main component of MV, has been widely used in the clinical practice. However, the PEEP selection is still a difficult problem for moderate to severe ARDS patients. EIT, an imaging tool evaluating the regional ventilation distribution at the bedside, can achieve the individual PEEP selection for all mechanically ventilated patients. Our previous study found that moderate to severe ARDS patients with higher recruitability could benefit from EIT-guided PEEP. This article compared the effect of PEEP titrated guided by EIT with fraction of inspired oxygen (FiO2)-PEEP table on the clinical outcomes in ARDS patients.

Eligibility

Sex
ALL
Min age
19 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age≥18 years 2. Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen \[PaO2\]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O) 3. Diagnosis of ARDS less than 72 hours Exclusion Criteria: 1. Expected to be mechanically ventilated for less than 48 hours 2. Severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive MV 3. Undrained pneumothorax or subcutaneous emphysema 4. Contraindication to the use of EIT (pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps) 5. Severe neuromuscular disease 6. Hemodynamic instability 7. Contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome 8. Severe other organs dysfunction with a low expected survival (7 days) or palliative care 9. Severe liver disease (Child-Pugh Score ≥10) 10. Pregnancy 11. Refusal to sign the informed consent

Primary outcome measure(s)

Trial sites (17)

FacilityCityRegionStatus
Second Hospital of Anhui Medical University Hefei Anhui Not Yet Recruiting
Department of Critical Care Medicine, Zhongshan Hospital of Fudan University Shanghai China Mainland Recruiting
Department of Critical Care Medicine, Renji Hospital Shanghai China Mainland Not Yet Recruiting
The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong Not Yet Recruiting
Zhengzhou Central Hospital Affiliated to Zhengzhou University Zhengzhou Henan Not Yet Recruiting
The Affiliated Hospital of Hangzhou Normal University Hangzhou Jiangsu Not Yet Recruiting
Zhongda Hospital, School of Medicine, Southeast University Nanjing Jiangsu Recruiting
The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu Not Yet Recruiting
The First Affiliated Hospital of Nanchang University Nanchang Jiangxi Not Yet Recruiting
Qinghai University Affiliated Hospital Xining Qinghai Not Yet Recruiting
First Affiliated Hospital of Xi'an Jiaotong University Xian Shanxi Not Yet Recruiting
People's Hospital of Quzhou Quzhou Zhejiang Not Yet Recruiting
Affiliated Beijing Chaoyang Hospital of Capital Medical University Beijing China Not Yet Recruiting
Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine Hangzhou China Not Yet Recruiting
Ruijin Hospital Shanghai Jiaotong University School Of Medicine Shanghai China Not Yet Recruiting
Asan Medical Center Seoul South Korea Not Yet Recruiting
Taichung Veterans General Hospital Taichung Taiwan Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06990477 on ClinicalTrials.gov ↗ ← All trials in South Korea